Abera Bioscience is active in biotechnology. The company specializes in the development of vaccines based on its own internal developed and patented platform. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and oncology. The business is located around the Nordic market. The company was founded in 2012 and is headquartered in Solna.

Quotes for Abera Bioscience AB

Right Now

+/-
-0.36
%
−6,04%
Latest
5.6
High
5.92
Low
5.6
Volume
2 215
Turnover (SEK)
12 525
Market Value (MSEK)
86,0
Time (Latest trade)

Board

CEO

  • Maria Alriksson

Chairperson of the Board

  • Anders Ericsson

Board

  • Sohila Zadar
  • Cristina Glad
  • Fredrik Juserius
  • Harry Råstedt
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Abera's vaccine platform BERA - short explanation

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 12,21 12,21 2024-12-23
    Nordnet Pensionsförsäkring 8,26 8,26 2024-12-23
    Anders Ericsson med familj 6,18 6,18 2022-05-17
    Jan-Willem De Gier 3,88 3,88 2024-12-23
    Joen Luirink 3,80 3,80 2024-12-23
    Stefan Olsson 3,38 3,38 2024-12-23
    Anders Wall stiftelser 2,09 2,09 2024-12-23
    Handelsbanken Liv Försäkring AB 2,07 2,07 2024-12-23
    Maths Wahlström 2,03 2,03 2024-12-23
    Agneta Albinsson 2,03 2,03 2024-12-23
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-05-13 Delårsrapport 2025-Q1

    • 2025-06-11 Årsstämma 2024

    • 2025-08-21 Delårsrapport 2025-Q2

    • 2025-11-13 Delårsrapport 2025-Q3

    • 2026-02-12 Bokslutskommuniké 2025

    Annual reports, prospectus etc.